XML 30 R19.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS

3 Months Ended

Mar. 31, 2012

13.

CONCENTRATIONS

Major Customers

For the three months ended March 31, 2012, approximately 27% of the Company’s revenues was received from one customer. For the three months ended March 31, 2011, approximately 18% of the Company’s revenues was received from one customer.

At March 31, 2012 and 2011, receivables from four customers were approximately 11%, 9%, 8%, 8% and 12%, 11%, 11%, 10%, respectively.

Revenues

For the three months ended March 31, 2012 and 2011, the Company’s three top selling products accounted, in the aggregate, for approximately 81% and 90%, respectively, of its total net revenues.

The following represents the revenues by product line, all derived from China:

	For the three months ended March 31,
	2012		2011
Product Line	US$		US$

Medical Devices		2,924,301		2,743,701
Respiratory and Oxygen Homecare		391,630		209,005
		3,315,931		2,952,706

Subsequent Events

The Company issued 5,000 shares to an investor relationship consultant on April 5, 2012 pursuant to a consulting agreement signed on January 9, 2012. The fair value of the shares granted on April 5, 2012 was approximately $12,000 based on the closing price on that date.

On April 23, 2012, the Company signed a strategic cooperation agreement with Timesco of London Ltd., to be its exclusive distributor in mainland China for Timesco’s entire laryngoscope Optima series of products in the next three years.